On February 5, 2024, GSK announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating belantamab mafodotin combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma. These data will be presented at the American Society of Clinical Oncology (ASCO) Plenary Series on 6 February 2024. Read the full press release to learn more.